JOP20230044A1 - مركبات وتركيبات كمثبطات sspl2a - Google Patents

مركبات وتركيبات كمثبطات sspl2a

Info

Publication number
JOP20230044A1
JOP20230044A1 JOJO/P/2023/0044A JOP20230044A JOP20230044A1 JO P20230044 A1 JOP20230044 A1 JO P20230044A1 JO P20230044 A JOP20230044 A JO P20230044A JO P20230044 A1 JOP20230044 A1 JO P20230044A1
Authority
JO
Jordan
Prior art keywords
inhibitors
formulations
sspl2a
compounds
sppl2a
Prior art date
Application number
JOJO/P/2023/0044A
Other languages
Arabic (ar)
English (en)
Inventor
Claus Ehrhardt
Robert Epple
Trixi Brandl
Pascal Rigollier
Juraj Velcicky
Christian Markert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20230044A1 publication Critical patent/JOP20230044A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOJO/P/2023/0044A 2020-09-17 2023-02-27 مركبات وتركيبات كمثبطات sspl2a JOP20230044A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063079604P 2020-09-17 2020-09-17
PCT/IB2021/058398 WO2022058902A1 (en) 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors

Publications (1)

Publication Number Publication Date
JOP20230044A1 true JOP20230044A1 (ar) 2023-02-27

Family

ID=77897680

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0044A JOP20230044A1 (ar) 2020-09-17 2023-02-27 مركبات وتركيبات كمثبطات sspl2a

Country Status (30)

Country Link
US (1) US20230365571A1 (https=)
EP (2) EP4578451A3 (https=)
JP (2) JP7771172B2 (https=)
KR (1) KR20230069947A (https=)
AU (1) AU2021342783A1 (https=)
CA (1) CA3192763A1 (https=)
CL (2) CL2023000728A1 (https=)
CO (1) CO2023004646A2 (https=)
CR (1) CR20230142A (https=)
DK (1) DK4214210T3 (https=)
DO (1) DOP2023000055A (https=)
EC (1) ECSP23027092A (https=)
ES (1) ES3028668T3 (https=)
FI (1) FI4214210T3 (https=)
GE (2) GEAP202516217A (https=)
HR (1) HRP20250562T1 (https=)
HU (1) HUE071569T2 (https=)
IL (1) IL300953B1 (https=)
JO (1) JOP20230044A1 (https=)
LT (1) LT4214210T (https=)
MA (1) MA61557B1 (https=)
MD (1) MD4214210T2 (https=)
MX (1) MX2023003122A (https=)
PE (1) PE20231099A1 (https=)
PL (1) PL4214210T3 (https=)
PT (1) PT4214210T (https=)
RS (1) RS66874B1 (https=)
SI (1) SI4214210T1 (https=)
SM (1) SMT202500216T1 (https=)
WO (1) WO2022058902A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116947813A (zh) * 2023-07-06 2023-10-27 绍兴贝斯美化工股份有限公司 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法
US20250263416A1 (en) 2024-02-15 2025-08-21 Incyte Corporation SPPL2a INHIBITORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
GB9612622D0 (en) 1996-06-17 1996-08-21 Zeneca Ltd Chemical process
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
WO2015160772A1 (en) 2014-04-15 2015-10-22 Janssen Pharmaceutica Nv Tetrahydro-benzoimidazolyl modulators of tgr5

Also Published As

Publication number Publication date
DOP2023000055A (es) 2023-06-15
CO2023004646A2 (es) 2023-07-21
SI4214210T1 (sl) 2025-07-31
JP2023541475A (ja) 2023-10-02
MD4214210T2 (ro) 2025-10-31
HUE071569T2 (hu) 2025-09-28
EP4578451A3 (en) 2025-09-17
AU2021342783A9 (en) 2024-09-12
EP4578451A2 (en) 2025-07-02
KR20230069947A (ko) 2023-05-19
MX2023003122A (es) 2023-03-22
CN116615425A (zh) 2023-08-18
PT4214210T (pt) 2025-05-22
IL300953A (en) 2023-04-01
AU2021342783A1 (en) 2023-05-18
WO2022058902A1 (en) 2022-03-24
IL300953B1 (en) 2026-04-01
PL4214210T3 (pl) 2025-08-18
ECSP23027092A (es) 2023-06-30
JP2026041723A (ja) 2026-03-10
CL2023000728A1 (es) 2023-12-15
CR20230142A (es) 2023-08-25
CA3192763A1 (en) 2022-03-24
EP4214210B1 (en) 2025-04-09
MA61557B1 (fr) 2025-05-30
SMT202500216T1 (it) 2025-07-22
HRP20250562T1 (hr) 2025-07-04
ES3028668T3 (en) 2025-06-19
GEAP202516217A (en) 2025-02-10
LT4214210T (lt) 2025-07-25
GEP20257771B (en) 2025-06-10
DK4214210T3 (da) 2025-06-10
RS66874B1 (sr) 2025-06-30
EP4214210A1 (en) 2023-07-26
JP7771172B2 (ja) 2025-11-17
PE20231099A1 (es) 2023-07-18
US20230365571A1 (en) 2023-11-16
CL2024001312A1 (es) 2024-10-11
FI4214210T3 (fi) 2025-05-26

Similar Documents

Publication Publication Date Title
JOP20230044A1 (ar) مركبات وتركيبات كمثبطات sspl2a
GEP20247710B (en) Small molecule inhibitors of kras g12c mutant
JOP20210179A1 (ar) مثبطات إيميدازو[1، 2-b] بيريدازين IL-17A
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
HUP0301660A2 (hu) Neutrális endropeptidáz inhibitor (NEPI) vegyületek alkalmazása férfi szexuális mżködési zavar kezelésére és az azokat tartalmazó gyógyszerkészítmények
CR20220351A (es) Inhibidores de proteínas kras mutantes
SA522440778B1 (ar) Rip1k مثبطات
BR0309281A (pt) Triaril-oxi-espiro-pirimidino-2,4,6-trionas inibidoras de metaloproteinases
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
EP0677048A1 (en) CYCLIC SULPHONES AS INHIBITORS RETROVIRAL PROTEASES.
ES2134275T3 (es) Inhibidores de la farnesil-protein transferasa.
ES2150933T3 (es) Inhibidores de la proteasa vih utiles para el tratamiento del sida.
DK1029921T3 (da) Serpinresistent t-PA, mutanter, gener
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
MX2024014480A (es) Composiciones farmaceuticas acuosas que comprenden inhibidores de sglt-2
GEAP202416532A (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2025036472A8 (en) Spirocyclic mta-cooperative prmt5 inhibitor
PT871454E (pt) Inibidores fosforosos que contem protease de cisteina e de serina
ZA202005325B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
JOP20220291A1 (ar) مثبطات جلوكوزيل سيراميدز غير متعلقة بالجسم الحال واستخداماتها
ATE443044T1 (de) Tace inhibitoren